← Eichor
Condition: Systemic Juvenile Idiopathic Arthritis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Systemic Juvenile Idiopathic Arthritis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Phase N/A · 1 location(s) · Children's National Research Institute · NCT04833465Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, a
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT03510442A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07517250Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Phase N/A · 1 location(s) · Université Catholique de Louvain · NCT07000916AutoInflammatory Disease Alliance Registry (AIDA)
Phase N/A · 112 location(s) · University of Siena · NCT05200715Rheumatology Patient Registry and Biorepository
Phase N/A · 1 location(s) · Yale University · NCT04402086Ilaris NIS in Korea
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT06838143Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT04902807Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Phase N/A · 9 location(s) · Peking Union Medical College Hospital · NCT06417502Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05927454Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Even
Phase 3 · 47 location(s) · AbbVie · NCT05609630Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07184450A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYP
Phase 2 · 32 location(s) · Sanofi · NCT02991469EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07077304To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic A
NA · 10 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT05925452Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Phase 4 · 2 location(s) · University of Sao Paulo General Hospital · NCT07087912A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Phase 3 · 79 location(s) · Eli Lilly and Company · NCT03773965Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Phase 2 · 1 location(s) · NYU Langone Health · NCT07138898A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participant
Phase 2 · 22 location(s) · Novartis Pharmaceuticals · NCT07203001
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.